Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine

Clinical and Diagnostic Laboratory Immunology

Volumn 3, Issue 6, 1996, Pages 769-773

  Gorse, Geoffrey J ^a   Yang, Ellen Y ^a,c   Belshe, Robert B ^a   Berman, Phillip W ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c S Louis Univ School of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SALIVA;

EID: 0029908491     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.3.6.769-773.1996     Document Type: Article

References (18)

1. Archibald, D. W., C. A. Herbert, D. Sun, and C. O. Tacket. 1990. Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial. J. Acquired Immune Defic. Syndr. 3:954-958.
2. Barrett, N., G. Eder, and F. Dorner. 1990-91. Characterization of a vacciniaderived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Biotechnol. Ther. 2:91-106.
3. Belshe, R. B., B. S. Graham, M. C. Keefer, G. J. Gorse, P. Wright, R. Dolin, T. Matthews, K. Weinhold, D. P. Bolognesi, R. Sposto, D. M. Stablein, T. Twadell, P. W. Berman, T. Gregory, A. E. Izu, M. C. Walker, and P. Fast for the NIAID AIDS Vaccine Clinical Trials Network. 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272:475-180.
4. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gpl60. Nature (London) 345:622-625.
5. Berman, P. W., T. J. Matthews, L. Riddle, M. Champe, M. R. Hobbs, G. R. Nakamura, J. Mercer, D. J. Eastman, C. Lucas, A. J. Langlois, F. M. Wurm, and T. J. Gregory. 1992. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:4464-4469.
6. Burnett, P. R., T. C. VanCott, V. R. Polonis, R. R. Redfield, and D. L. Birx. 1994. Serum IgA-mediated neutralization of HIV type 1. J. Immunol. 152:4642-4648.
7. Centers for Disease Control and Prevention. 1995. HIV/AIDS Surveillance Report 7(2):l-39.
8. Cranage, M. P., A. Baskenille, L. A. E. Ashworth, M. Dennis, N. Cook, S. Sharpe, G. Farrar, J. Rose, P. A. Kitchin, and P. J. Greenaway. 1992. Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 339:273-274.
9. De Vincenzi, I., for the European Study Group on Heterosexual Transmission of HIV. 1994. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N. Engl. J. Med. 331:341-346.
10. Forrest, B. D. 1991. Women, HIV, and mucosal immunity. Lancet 337:835-836.
11. Forrest, B. D. 1992. Mucosal approaches to HIV vaccine development. AIDS Res. Hum. Retroviruses 8:1523-1525.
12. Fultz, P. N., P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard. 1992. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 256:1687-1690.
13. Funkhouser, A., M. L. Clements, S. Salome, B. dayman, and R. Viscidi. 1993. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients. AIDS Res. Hum. Retroviruses 9:627-632.
14. Gorse, G. J., J. H. Rogers, J. E. Perry, F. K. Newman, S. E. Frey, G. B. Patel, and R. B. Belshe for the NIAID AIDS Vaccine Clinical Trials Network. 1995. HIV-1 recombinant gpl60 vaccine induced antibodies in serum and saliva. Vaccine 13:209-214.
15. Janoff, E. N., S. M. Wahl, K. Thomas, and P. D. Smith. 1995. Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. J. Infect. Dis. 172:855-558.
16. Kozlowski, P. A., K. P. Black, L. Shen, and S. Jackson. 1995. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons, masking by IgG. J. Immunol. 154:6163-6173.
17. Kozlowski, P. A., D. Chen, J. H. Eldridge, and S. Jackson. 1994. Contrasting IgA and IgG neutralization capacities and responses to the HIV-1 gp120 V3 loop in HIV-infected individuals. AIDS Res. Hum. Retroviruses 10:813-822.
18. Marx, P. A., R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamschchikov, D. Chen, and J. H. Eldridge. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323-1327.